与心肌缺血再灌注损伤相关的新型心肌保护分子靶点研究进展

doi:10.3969/j.issn.1674-490X.2020.03.001

摘要/Abstract

摘要： 急性心肌梗死(acute myocardial infarction, AMI)及心力衰竭并发症的发病率和病死率在全世界仍然居高不下。经证实AMI后冠状动脉的早期再灌注是典型而有效的治疗方法,但侧支及心肌缺血再灌注损伤(myocardial ischemia reperfusion injury,MIRI)及相关的心脏保护机制尚不清楚。因此,研究触发和治疗MIRI病理生理学的相关新型分子靶点有重要意义。特别关注由分子药理学支持的MIRI的最新进展,以此简单阐述参与预防和抗心肌缺血再灌注损伤的最新分子靶点, 以期为心肌缺血再灌注损伤的机制研究与新药研发提供思路。

关键词: 心肌缺血, 缺血再灌注损伤, 线粒体因子, 免疫分子靶点

Abstract: Worldwide morbidity and mortality of acute myocardial infarction(AMI)and related heart failure are still high. While effective early reperfusion of the criminal coronary artery after a confirmed AMI is the typical and effective treatment at present, collateral myocardial ischemia reperfusion injury(MIRI)and pertinent cardioprotection are still challenging to address and have inadequately understood mechanisms. Therefore, unveiling the related novel molecular targets and networks participating in triggering and resisting the pathobiology of MIRI is a promising and valuable frontier. The present study specifically focuses on the recent MIRI advances that are supported by sophisticated molecular pharmacology in order to bring the poorly understood interrelationship among MIRI participant molecules up to date, as well as to identify findings that may facilitate the new drug of novel targets.

Key words: myocardial ischemia, ischemia reperfusion injury, mitochondrial factors, immune molecular targets

中图分类号:

R542.2

侯凯,李运曼. 与心肌缺血再灌注损伤相关的新型心肌保护分子靶点研究进展[J]. 医学研究与教育, 2020, 37(3): 1-9.

参考文献

[1] ANDERSON J L, MORROW D A. Acute myocardial infarction[J]. N Engl J Med, 2017, 376(21): 2053-2064. DOI: 10.1056/NEJMra1606915.
[2] HAUSENLOY D J, YELLON D M. Myocardial ischemia-reperfusion injury: a neglected therapeutic target[J]. J Clin Invest, 2013, 123(1): 92-100. DOI: 10.1172/JCI62874.
[3] BØTKER H E, HAUSENLOY D, ANDREADOU I, et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection[J]. Basic Res Cardiol, 2018, 113(5): 39. DOI: 10.1007/s00395-018-0696-8.
[4] DE JONG R C M, PLUIJMERT N J, DE VRIES M R, et al. Annexin A5 reduces infarct size and improves cardiac function after myocardial ischemia-reperfusion injury by suppression of the cardiac inflammatory response[J]. Sci Rep, 2018, 8(1): 6753. DOI: 10.1038/s41598-018-25143-y.
[5] LESNEFSKY E J, CHEN Q, TANDLER B, et al. Mitochondrial dysfunction and myocardial ischemia-reperfusion: implications for novel therapies[J]. Annu Rev Pharmacol Toxicol, 2017, 57: 535-565. DOI: 10.1146/annurev-pharmtox-010715-103335.
[6] GRANGER D N, KVIETYS P R. Reperfusion injury and reactive oxygen species: the evolution of a concept[J]. Redox Biol, 2015, 6: 524-551. DOI: 10.1016/j.redox.2015.08.020.
[7] ONG S B, HERNÁNDEZ-RESÉNDIZ S, CRESPO-AVILAN G E, et al. Inflammation following acute myocardial infarction: multiple players, dynamic roles, and novel therapeutic opportunities[J]. Pharmacol Ther, 2018, 186: 73-87. DOI: 10.1016/j.pharmthera.2018.01.001.
[8] SWIRSKI F K, NAHRENDORF M. Cardioimmunology: the immune system in cardiac homeostasis and disease[J]. Nat Rev Immunol, 2018, 18(12): 733-744. DOI: 10.1038/s41577-018-0065-8.
[9] KURIAN G A, RAJAGOPAL R, VEDANTHAM S, et al. the role of oxidative stress in myocardial ischemia and reperfusion injury and remodeling: revisited[J]. Oxid Med Cell Longev, 2016, 2016: 1656450. DOI: 10.1155/2016/1656450.
[10] BANU S A, RAVINDRAN S, KURIAN G A. Hydrogen sulfide post-conditioning preserves interfibrillar mitochondria of rat heart during ischemia reperfusion injury[J]. Cell Stress Chaperones, 2016, 21(4): 571-582. DOI: 10.1007/s12192-016-0682-8.
[11] KORGE P, JOHN S A, CALMETTES G, et al. Reactive oxygen species production induced by pore opening in cardiac mitochondria: the role of complex II[J]. J Biol Chem, 2017, 292(24): 9896-9905. DOI: 10.1074/jbc.M116.768325.
[12] KOHLHAUER M, DAWKINS S, COSTA A S H, et al. Metabolomic profiling in acute ST-segment-elevation myocardial infarction identifies succinate as an early marker of human ischemia-reperfusion injury[J]. J Am Heart Assoc, 2018, 7(8): e007546. DOI: 10.1161/JAHA.117.007546.
[13] PARADIS S, LEONI V, CACCIA C, et al. Cardioprotection by the TSPO ligand 4'-chlorodiazepam is associated with inhibition of mitochondrial accumulation of cholesterol at reperfusion[J]. Cardiovasc Res, 2013, 98(3): 420-427. DOI: 10.1093/cvr/cvt079.
[14] THACKERAY J T, HUPE H C, WANG Y, et al. Myocardial inflammation predicts remodeling and neuroinflammation after myocardial infarction[J]. J Am Coll Cardiol, 2018, 71(3): 263-275. DOI: 10.1016/j.jacc.2017.11.024.
[15] PARODI-RULLÁN R M, CHAPA-DUBOCQ X, RULLÁN P J, et al. Corrigendum: high sensitivity of SIRT3 deficient hearts to ischemia-reperfusion is associated with mitochondrial abnormalities[J]. Front Pharmacol, 2017, 8: 439. DOI: 10.3389/fphar.2017.00439.
[16] BOYLSTON J A, SUN J H, CHEN Y, et al. Characterization of the cardiac succinylome and its role in ischemia-reperfusion injury[J]. J Mol Cell Cardiol, 2015, 88: 73-81. DOI: 10.1016/j.yjmcc.2015.09.005.
[17] SLUIJTER J P, CONDORELLI G, DAVIDSON S M, et al. Novel therapeutic strategies for cardioprotection[J]. Pharmacol Ther, 2014, 144(1): 60-70. DOI: 10.1016/j.pharmthera.2014.05.005.
[18] ZHANG W L, CHEN C Y, WANG J, et al. Mitophagy in cardiomyocytes and in platelets: a major mechanism of cardioprotection against ischemia/reperfusion injury[J]. Physiology(Bethesda), 2018, 33(2): 86-98. DOI: 10.1152/physiol.00030.2017.
[19] ZHANG W L, SIRAJ S, ZHANG R, et al. Mitophagy receptor FUNDC1 regulates mitochondrial homeostasis and protects the heart from I/R injury[J]. Autophagy, 2017, 13(6): 1080-1081. DOI: 10.1080/15548627.2017.1300224.
[20] CHOUCHANI E T, PELL V R, GAUDE E, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS[J]. Nature, 2014, 515(7527): 431-435. DOI: 10.1038/nature13909.
[21] VALLS-LACALLE L, BARBA I, MIRÓ-CASAS E, et al. Succinate dehydrogenase inhibition with malonate during reperfusion reduces infarct size by preventing mitochondrial permeability transition[J]. Cardiovasc Res, 2016, 109(3): 374-384. DOI: 10.1093/cvr/cvv279.
[22] BRADLEY J M, LI Z, ORGAN C L, et al. A novel mtDNA repair fusion protein attenuates maladaptive remodeling and preserves cardiac function in heart failure[J]. Am J Physiol Heart Circ Physiol, 2018, 314(2): H311-H321. DOI: 10.1152/ajpheart.00515.2017.
[23] CHANG C, JI Q W, WU B W, et al. Chemerin15-ameliorated cardiac ischemia-reperfusion injury is associated with the induction of alternatively activated macrophages[J]. Mediators Inflamm, 2015, 2015: 563951. DOI: 10.1155/2015/563951.
[24] YUE Y, YANG X, FENG K N, et al. M2b macrophages reduce early reperfusion injury after myocardial ischemia in mice: a predominant role of inhibiting apoptosis via A20[J]. Int J Cardiol, 2017, 245: 228-235. DOI: 10.1016/j.ijcard.2017.07.085.
[25] CANNA S W, GOLDBACH-MANSKY R. Introduction: autoinflammatory syndromes special issue-hidden mysteries in the corners of autoinflammation[J]. Int Immunol, 2018, 30(5): 181-182. DOI: 10.1093/intimm/dxy022.
[26] SZYMANSKI A M, OMBRELLO M J. Using genes to triangulate the pathophysiology of granulomatous autoinflammatory disease: NOD2, PLCG2 and LACC1[J]. Int Immunol, 2018, 30(5): 205-213. DOI: 10.1093/intimm/dxy021.
[27] GOLDSMITH J R, CHEN Y H. Regulation of inflammation and tumorigenesis by the TIPE family of phospholipid transfer proteins[J]. Cell Mol Immunol, 2017, 14(12): 1026. DOI: 10.1038/cmi.2017.127.
[28] ROSSELLO X, RIQUELME J A, DAVIDSON S M, et al. Role of PI3K in myocardial ischaemic preconditioning: mapping pro-survival cascades at the trigger phase and at reperfusion[J]. J Cell Mol Med, 2018, 22(2): 926-935. DOI: 10.1111/jcmm.13394.
[29] LIU Y, YANG H, LIU L X, et al. NOD2 contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and inflammation[J]. Life Sci, 2016, 149: 10-17. DOI: 10.1016/j.lfs.2016.02.039.
[30] PARAPANOV R, LUGRIN J, ROSENBLATT-VELIN N, et al. Toll-like receptor 5 deficiency exacerbates cardiac injury and inflammation induced by myocardial ischaemia-reperfusion in the mouse[J]. Clin Sci, 2015, 129(2): 187-198. DOI: 10.1042/CS20140444.
[31] HAMID T, PRABHU S D. Immunomodulation is the key to cardiac repair[J]. Circ Res, 2017, 120(10): 1530-1532. DOI: 10.1161/CIRCRESAHA.117.310954.
[32] XIA N, JIAO J, TANG T T, et al. Activated regulatory T-cells attenuate myocardial ischaemia/reperfusion injury through a CD39-dependent mechanism[J]. Clin Sci, 2015, 128(10): 679-693. DOI: 10.1042/CS20140672.
[33] RAMJEE V, LI D Q, MANDERFIELD L J, et al. Epicardial YAP/TAZ orchestrate an immunosuppressive response following myocardial infarction[J]. J Clin Invest, 2017, 127(3): 899-911. DOI: 10.1172/JCI88759.
[34] FANG J, HU F D, KE D, et al. N, N-dimethylsphingosine attenuates myocardial ischemia-reperfusion injury by recruiting regulatory T cells through PI3K/Akt pathway in mice[J]. Basic Res Cardiol, 2016, 111(3): 32. DOI: 10.1007/s00395-016-0548-3.
[35] GOLTZ D, HUSS S, RAMADORI E, et al. Immunomodulation by splenectomy or by FTY720 protects the heart against ischemia reperfusion injury[J]. Clin Exp Pharmacol Physiol, 2015, 42(11): 1168-1177. DOI: 10.1111/1440-1681.12465.
[36] HEUSCH G, GERSH B J. The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: a continual challenge[J]. Eur Heart J, 2017, 38(11): 774-784. DOI: 10.1093/eurheartj/ehw224.
[37] RIZK F H, ABDEL GHAFAR M T, SOLIMAN N A, et al. Vildagliptin recruits regulatory T cells in patients undergoing primary percutaneous coronary intervention[J]. Immunol Invest, 2018, 47(6): 583-592. DOI: 10.1080/08820139.2018.1467927.
[38] MOFID A, NEWMAN N S, LEE P J, et al. Cardiac overexpression of S100A6 attenuates cardiomyocyte apoptosis and reduces infarct size after myocardial ischemia-reperfusion[J]. J Am Heart Assoc, 2017, 6(2): e004738. DOI: 10.1161/JAHA.116.004738.
[39] DE JONG R C M, PLUIJMERT N J, DE VRIES M R, et al. Annexin A5 reduces infarct size and improves cardiac function after myocardial ischemia-reperfusion injury by suppression of the cardiac inflammatory response[J]. Sci Rep, 2018, 8(1): 6753. DOI: 10.1038/s41598-018-25143-y.
[40] ZOU R J, SHI W T, TAO J, et al. SIRT5 and post-translational protein modifications: a potential therapeutic target for myocardial ischemia-reperfusion injury with regard to mitochondrial dynamics and oxidative metabolism[J]. Eur J Pharmacol, 2018, 818: 410-418. DOI: 10. 1016/j.ejphar.2017.11.005.